Demodex blepharitis: cross-border specialty drug access for international patients

Quick orientation

Demodex mites are present in the lash follicles of an estimated 25 percent of adults under 40 and substantially higher rates in older adults. Symptomatic demodex blepharitis affects an estimated 25 million Americans, with similar relative prevalence globally.

Typical age of onset. Any adult age; prevalence increases with age.

Severity tiers. Symptoms range from mild irritation and itching to chronic eyelid inflammation and meibomian gland dysfunction.

Why specialty drugs for Demodex blepharitis are hard to access internationally

Xdemvy (lotilaner ophthalmic solution), approved by the FDA in 2023, is the first prescription therapy specifically labeled for demodex blepharitis. International registration is in early stages and the product is not yet widely available outside the US.

Treatments approved by the FDA

• Xdemvy (lotilaner ophthalmic solution 0.25 percent) — FDA approval: 2023. Mechanism: Selective parasiticide for demodex mites. Route: Topical ophthalmic twice daily for 6 weeks. US WAC ballpark: Approximately USD 1,800 to 2,500 per 6-week course. Country pricing: UAE · Saudi Arabia · India · Egypt · Lebanon.

Cross-border pathways used for Demodex blepharitis

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Personal Import Scheme
• Cross-border Prescription

What your physician needs to know

• Confirm demodex involvement by slit-lamp examination of cylindrical dandruff at lash bases.
• Document failure of standard lid hygiene measures.
• Course is 6 weeks; recurrence is possible and may warrant repeat treatment.
• Some destination countries require ophthalmologist or optometrist prescription for ophthalmic specialty drugs.

Common questions

Is Xdemvy approved outside the United States?

Approval status varies. International rollout is in early stages.

How long is a course?

Six weeks of twice-daily dosing per the label.

Will the mites come back?

Recurrence is possible. Some patients require periodic re-treatment.

Do I need a prescription?

Yes. Reserve Meds requires a prescription from your treating ophthalmologist or optometrist.

What documents are required?

Prescription and clinical summary noting the demodex findings.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Demodex blepharitis, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Demodex blepharitis

Reserved for you.